← All Skinvisible, INC filings

Skinvisible, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OQB
SKVI
Skinvisible, INC
10-K: Skinvisible Reports Deepening Losses Amid Promising Clinical Progress
Skinvisible Inc. reported a significant increase in net loss for fiscal year 2025, raising substantial doubt about its going concern status, despite ongoing positive clinical trial developments for its Invisicare technology.
OQB
SKVI
Skinvisible, INC
10-K: Skinvisible, Inc. Reports 2024 Annual Results, Cites Progress in Invisicare Licensing and Development
Skinvisible, Inc. files its 10-K for the year ended December 31, 2024, highlighting ongoing efforts to license its Invisicare technology and advancements in clinical trials by its licensee, Quoin Pharmaceuticals.
OQB
SKVI
Skinvisible, INC
10-K: Skinvisible Inc. Reports Full Year 2023 Results, Cites Progress in Clinical Trials
Skinvisible, Inc. reports a net loss of $2.38 million for 2023, while highlighting advancements in clinical trials by its licensee, Quoin Pharmaceuticals.